Sanofi, BEYFORTUS
Sanofi begins shipping BEYFORTUS to US for RSV prevention in infants
French multinational pharmaceutical company Sanofi has commenced the shipping of BEYFORTUS (nirsevimab-alip) to the US, targeting both private healthcare providers and the Centers for Disease Control and Prevention's Vaccines for Children programme,
Sanofi shipping RSV jab Beyfortus in USA
French pharma major Sanofi today revealed it is shipping Beyfortus (nirsevimab-alip) 50mg and 100mg Injection doses in the USA to private healthcare providers and to the Centers for Disease Control and Prevention.
Sanofi, AstraZeneca win US approval for RSV therapy manufacturing line
Sanofi said on Monday the U.S. Food and Drug Administration has approved a manufacturing line for its and partner AstraZeneca's preventive respiratory syncytial virus (RSV) therapy.
Sanofi Shipping BEYFORTUS® In US To Help Protect Babies Against RSV Disease New Manufacturing Line Approved By FDA
Company planning for every eligible baby in the US to have access to BEYFORTUS <li /> New BEYFORTUS filling line approved by the
Sanofi To Offer BEYFORTUS Doses To Protect Babies During RSV Season - Quick Facts
Sanofi (SNYNF, SNY) said it is shipping BEYFORTUS 50mg and 100mg Injection doses in the US to private healthcare providers and to the
Sanofi, AstraZeneca win approval for RSV therapy manufacturing line
Sanofi and partner AstraZeneca have received approval from the U.S. Food and Drug Administration for a manufacturing line for their preventive respiratory
FiercePharma6d
With amped up manufacturing effort, Sanofi and AZ look to avoid Beyfortus shortfalls this year
As this year’s respiratory syncytial virus (RSV) season approaches, Beyfortus makers Sanofi and AstraZeneca are making ...
Zacks.com on MSN3d
Sanofi Stock Up Almost 23% in 3 Months: Buy, Sell or Hold?
Sanofi’s SNY stock has gained 22.7% in the past three months compared with an increase of 2.9% for the industry. The stock ...
BioPharma Dive6d
Sanofi readies to meet US demand for RSV antibody
With a new production line, Sanofi aims to keep it and partner AstraZeneca’s drug Beyfortus in fully supply this RSV season.
Sanofi: A Strong Buy on Earnings Growth, Pipeline Progress, and Market Catalysts
Analyst Graham Parry of Bank of America Securities maintained a Buy rating on Sanofi (SNYNF – Research Report), retaining the price ...
TBR News Media3d
Local doctors recommend flu and covid shots within the next few weeks
With the peak flu season often occurring during December and January and even into February, Dr. Sharon Nachman, Chief of the ...
ENDPOINTS NEWS4d
Bio­Cen­triq names ex-Re­silient ex­ec as new CEO; Sanofi, As­traZeneca boost Bey­for­tus pro­duc­tion
Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and ...
Sanofi (SNYNF) Receives a Buy from Barclays
Barclays analyst Emily Field maintained a Buy rating on Sanofi (SNYNF – Research Report) today and set a price target of €120.00. The ...